• MAZAKALI’s management team has vast experience in the cannabis industry, helping uniquely position the company to dominate one of the fastest-growing industries in the world
• The MAZAKALI management team has extensive experience at Fortune 500 companies, including UBS, JP Morgan, Merrill Lynch, Apple, AliBaba and AT Kearney
• The cannabis market is expected to reach $73.6 billion by 2027, growing at a CAGR of 27%
• The company places authority and knowledge on the same pedestal, providing GreenPapers(R) as a valuable educational tool for the public on all topics and trends related to the high-growth cannabis industry; over 70 GreenPapers(R) have been published since 2016, attracting over 70,000 subscribers to date
• The MAZAKALI investment team is comprised of licensed investment bankers and Registered Investment Advisors; securities are offered via a registered broker/dealer
• MAZAKALI’s online marketplace serves cannabis capital formation with scalability, sustainability and sensibility
• MAZAKALI aims to create a healthier and sustainable world through the purposeful placement of capital

A cannabis-focused fintech marketplace based in San Francisco, MAZAKALI offers investment opportunities in the high growth cannabis industry. Supported by a broker/dealer and acting as a Registered Investment Adviser, the company has been supporting cannabis businesses in raising capital since 2016. MAZAKALI was founded to counteract the negative consequences of business practices by making investments in sustainable cannabis. By shepherding capital in a responsible and ethical manner, MAZAKALI and its clients envision a world where capital investment will play a significant role Beyond Impact. The company’s financial services leverage deep relationships, rigorous analytics and reliable research focused on uncovering investment opportunities in the high growth cannabis sector. The company features a deep bench of educated, experienced and licensed professionals to support clients with their capital and investment needs. Investor Services

• Online Investment Marketplace:Investors gain access to a pipeline of vetted investment opportunities; diversified across sectors and geography. In addition to direct investments, MAZAKALI offers managed funds and custom portfolios.
• Custom Portfolios:Investors seeking to place capital in excess of $1MM can take advantage of separately managed accounts designed and managed by licensed investment advisors. Custom portfolios offer several advantages over collective funds, including personalization, reduced expenses and tax benefits.
• Institutional Investor Services:MAZAKALI introduced the first Outsourced Cannabis Investment Officer (“OCIO”) service in 2019, providing its portfolio management expertise to those institutions with capital and interest seeking knowledge and access.

Issuer Services Every successful capital raise begins with proper preparation. Since its inception, MAZAKALI has specialized in supporting cannabis-related businesses by helping them prepare to raise capital. Cannabis firms that collaborate with MAZAKALI gain access to insight acquired through the hands-on experience of MAZAKALI’s management team. By providing comprehensive services throughout the entire fundraising process, MAZAKALI helps businesses save time and show well to potential investors at every stage. The company’s services include:

• Preparation stage:Initial consultation, business review, structural analysis, strategic planning, expansion agenda
• Structure offering stage:Capital advisory, capital cadence, deal structure, financial instrument selection, initial raise terms
• Modeling stage:Pro Forma financials, income statement, balance sheet, cash flow statement, assumption review, business valuation
• Pitch preparation stage:Pitch deck, investment deck, pitch practice, Q&A practice, pitch video
• Offer launch stage:Digital platform listing, pitch video, term sheet, Pro Forma model, financials, cap table, subscription docs, automated workflow, offer marketing

Education – GreenPapers(R) The company believes in ‘Authority Through Knowledge’. To help educate the public about the cannabis markets, MAZAKALI uses GreenPapers(R) to share deep trends and insights that matter to investors and operators alike. GreenPapers(R) archives span from 2016 to the present, with the most recent insight report focusing on major cannabis trends in 2021. Titled Cannabis 2021: Five Things to Watch, the report underlines that 2021 is poised to be a pivotal year for the cannabis sector amid growing political support, legalization in 70 percent of U.S. states, increased public focus and local governmental interest in gaining tax revenue from the market (https://ibn.fm/sAT1z). All of these factors and more are likely to make cannabis the best performing asset class of the decade, the report forecasts. The report also lists the five major trends expected in 2021:

• Rise of the cannabis beverage
• Biosynthesis
• Accelerated state and local market adoption
• Expanded capital participation
• Global growth

Technology MAZAKALI’s online marketplace was designed to provide compliance, convenience and confidence to the cannabis private equity investment process. The company’s investment services include education, research and execution on an intuitive digital interface. Investors can gain exposure to direct placements, managed accounts and third-party funds in a compliant and convenient marketplace. Market Outlook The global growth forecast by MAZAKALI is backed by other analysts and experts in the niche. According to Grand View Research, the global cannabis market is expected to grow exponentially amid increased acceptance of the plant worldwide. The industry is anticipated to reach $73.6 billion by 2027, expanding at a CAGR of 18.1%. In 2019, the largest revenue shares for cannabis belonged to North America, resulting in 88.4% of the worldwide market (https://ibn.fm/vmq3Z). According to a BCC Research report, the plant-based and botanical-derived drug market is also expected to grow globally and reach an estimated $39.6 billion valuation by 2022, marking a CAGR of 6.1% from the 2017 market value of $29.4 billion (https://ibn.fm/3f717). Management Team Sumit Mehta is the Founder and CEO of MAZAKALI. A cannabis strategist, Mr. Mehta is an internationally recognized speaker and the author of the MAZAKALI GreenPaper(R). In addition to his role leading MAZAKALI, Mr. Mehta serves on several cannabis company boards and is the Chair of the Banking and Financial Services committee for the National Cannabis Industry Association. Mr. Mehta is the former Director of Finance for the Arcview Group and, prior to entering the cannabis industry full-time in 2016, spent 20 years on Wall Street at firms including JP Morgan, UBS and Merrill Lynch. Mr. Mehta has earned an MBA from the Ross School of Business at the University of Michigan and a BA with Honors in Economics with minors in Math and Physics from the University of Texas at Austin. Mr. Mehta holds FINRA 7, 63, 65 and 79 licenses, as well as a Certificate in Financial Technology from Harvard University. Craig Piatti is the company’s Chief Operating Officer. He is responsible for developing and driving the firm’s infrastructure, technology and organizational processes. Prior to joining MAZAKALI, Mr. Piatti worked at Alibaba’s cloud computing division on strategic business development. He has also worked with global firms including SAP, Bosch and China Telecom. He holds an MBA from the University of Notre Dame – Mendoza College of Business and a BS from Indiana University – Kelly School of Business. He also holds a Diplom-Betriebswirt (“BWL”) from Reutlingen University in Germany and a FINRA 65 license. Mary Beth Barron is MAZAKALI’s Chief Marketing Officer. Ms. Barron leads the company’s marketing strategy, brand management, communications, advertising, public relations and digital marketing. Bringing more than 20 years of marketing and business leadership experience, her career started at Apple Far East (Hong Kong). She served as a top marketing leader for several global professional services – giving her marketing responsibilities in more than 30 countries. Ms. Barron holds an MBA from the Kellogg School of Management at Northwestern University and a BA from The Colorado College. Bob Peatman is the Director of Investments for MAZAKALI. Mr. Peatman is responsible for assisting wealth managers and investors with cannabis-related investment opportunities. Mr. Peatman has worked with retail and institutional investors throughout his financial career, with a focus on digitizing and expanding national sales distribution networks. He holds an MBA from Babson College and a BA from St. Lawrence University. Justin Schleifer is MAZAKALI’s Director of Compliance. Mr. Schleifer is responsible for developing the firm’s controls and overseeing its advisory business. He is also the CEO and Co-Founder of Aspect Advisors, a San Francisco-based compliance consulting firm for asset managers, broker-dealers and fintech businesses. Schleifer has extensive experience interfacing with the SEC, FINRA and the NFA. He earned his BS in Hotel Administration, concentrating in Business Law, from Cornell University. He also holds FINRA Series 7, 24, 27, 55, 66, 79 and 87 licenses. Mathew Auric serves as Legal Counsel for MAZAKALI. In his role, Mr. Auric is responsible for general legal support, including contract drafting and negotiation, internal business structuring, strategic planning and liability management. Mr. Auric is a corporate attorney with cannabusiness firm Hoban Law Group, with a deep understanding of the regulatory, practical and historical issues involving cannabis. He received his JD from Ventura College of Law and a bachelor’s degree from the University of California, Santa Cruz. For more information, visit the company’s website at www.MAZAKALI.com. NOTE TO INVESTORS: The latest news and updates relating to MAZAKALI are available in the company’s newsroom at https://ibn.fm/MAZAKALI

• Josemaria Resources developing its wholly owned flagship Josemaria Copper-Gold Project
• VanEck report details investment value of ‘junior’ mining companies
• Global smart mining market estimated to reach $6.8 billion last year, forecast to reach $20.31 billion by 2025

For investors looking for high-growth potential, junior mining companies may fit the bill, according to a recent report released by VanEck, an investment management company (https://ibn.fm/Cvv8W). That’s good news for Josemaria Resources (TSX: JOSE) (OTCQB: JOSMF), a natural resources company that is offering an advanced-stage copper-gold deposit project located in Argentina, a rare find in a junior mining company.

The VanEck report, titled “The Investment Case for Junior Gold Miners,” notes that “a dynamic and important subset of the global gold-mining industry is a group of companies known as ‘juniors.’ These are small- to medium-size market capitalization companies that are generally actively engaged in the development of new sources of gold either through greenfield exploration or the use of new geologic models to prospect for gold in overlooked or abandoned properties. For investors, juniors may offer characteristics similar to an investment in venture capital—early stage, high risk, but with a potential for high growth.”

Josemaria is looking for that type of high-growth return as it eyes key growth in a global smart mining market that was estimated to reach $6.8 billion last year and forecast to reach $20.31 billion by 2025 (https://ibn.fm/6Cc28). The company is focusing on the development of its wholly owned flagship Josemaria Copper-Gold Project located in the San Juan Province of Argentina. San Juan is a well-known mining hub supporting a wide variety of mining companies, where the Lundin Group, the parent company of JOSE, has been active for almost 30 years.

JOSE recently released the results of a feasibility study for its Josemaria Copper-Gold Project. The study reports a robust, rapid pay-back, low-risk project, with an open-pit operation feeding a conventional process plant at an average of 152,000 tonnes per day. The study also projected a mine life stretching more than 19 years and yielding average annual metal production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver.

“We are extremely pleased with the results of the Feasibility Study at Josemaria, which indicates that this is one of the very few readily developable copper-gold projects in the world today,” said Josemaria president and CEO Adam Lundin. “This study has materially de-risked the project and forecasts an attractive economic outcome which is comparable with other large-scale copper/gold projects already being developed or in production today.”

Josemaria Resources is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project. Josemaria Resources is part of the Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors around the world.

For more information on Josemaria Resources, visit the company’s website at www.JoseMariaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to JOSMF are available in the company’s newsroom at https://ibn.fm/JOSMF

• Company extends expiration of special dividend for one year
• If declared, special dividend will consist of number, designation determined by company management
• BIGtoken is first consumer-managed data marketplace where people can own, earn from their data

SRAX (NASDAQ: SRAX) will extend the expiration for its previously announced BIGtoken special dividend right for one year. The dividend right was set to expire on or before 5 p.m. on Dec. 31, 2020, and that deadline has been extended to on or before 5 p.m. ET on Dec. 31, 2021 (https://ibn.fm/sCKWJ). The original dividend right was issued on Sept. 17, 2018, when SRAX, then called Social Reality Inc., announced a nontransferable right to receive at no charge a special dividend to holders of the company’s Class A common stock; the right was also extended to certain holders of the company’s common stock equivalents. The extension announcement notes that “if and when declared, the Special Dividend will consist of such number and designation of the SRAX subsidiary BIGtoken Inc.’s securities as determined by the company’s management at their sole discretion. . . . The Special Dividend will be an analog security, i.e., not digital, and not a cryptocurrency, and the Special Dividend is expected to be a fractional non-voting security that, if and when issued, is expected to only participate in a portion of the financial performance of the BIGtoken platform.” Initially launched by SRAX and then spun off as a separate company, BIGtoken, or BIG, is a secure consumer data-management and distribution system —the first consumer-managed data marketplace where people can own and earn from their data (https://ibn.fm/nr4Sm). Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participants earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform (https://ibn.fm/gXpcG). At last count, BIGtoken has compensated more than 16 million users for access to their data while creating data sets across 25,000 unique market segments. Brands are offered access to this verified, opted-in data for a fee. “BIGtoken is a secure platform that empowers you to realize and claim the value of your digital self,” the website observes (https://ibn.fm/B0Cj3). “You have a right to privacy, awareness, and choice when it comes to the data you put out into the digital world. With BIG, you can own and earn from that data while staying connected to your community.” SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 1 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers
• Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain
• The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024
• CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, including the use of Berubicin for patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently working on the development and clinical trials of Berubicin for GBM and the potential of addressing other central nervous system malignancies.

Berubicin appears to be the first anthracycline to cross the blood-brain barrier in the adult brain. Its development started over 15 years ago when Reata Pharmaceuticals, Inc. (NASDAQ: RETA) conducted the first Phase I trial, creating limited clinical data. Phase I trial results indicated that 44 percent of participants reported a significant improvement in the size of the tumor. The evidence concluded that there was a positive enough impact that CNS has continued with the development and the clinical-stage trials for the drug.

CNS holds the exclusive license for Berubicin worldwide. The company goes into the year 2021 determined to move forward with the development and distribution of Berubicin for GBM. The recent approval of the United States Food and Drug Administration (“FDA”) of Berubicin as an investigational new drug (“IND”) has only increased the opportunity for CNS to move forward with the three clinical trials currently in development.

“The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans (https://ibn.fm/TP3oE).

The company’s sublicensee WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1) will be conducting a Phase II trial in adults, as well as the first-ever Phase I trial in children who suffer from GBM and other cancers of the brain and central nervous system. This is the first pediatric trial of its kind.

According to Climaco, CNS aims to address the significant unmet medical need of GBM patients since the current treatment paradigm for the condition yields bleak results, and this aggressive and, as yet, incurable form of brain cancer continues to claim high mortality rates. “We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial,” he added.

The GBM treatments market is anticipated to increase to an estimated $3.3 billion in 2014, marking a CAGR of 17.4% from 2014, when the market was $659. The growth is expected to be driven by seven major markets – the United States, Spain, the UK, France, Italy, Japan, and Germany, and is the direct result of the growing unmet needs of the current market (https://ibn.fm/ZAYjM).

Berubicin is currently being produced in two labs as a result of a dual-track manufacturing strategy implemented by CNS. To ensure that current conditions do not hinder the progress of Berubicin’s development and availability, CNS has turned to United States-based Pharmaceuticals International Inc. and Italy-based BSP Pharmaceuticals SpA for the production of Berubicin for the clinical trials. Both pharmaceutical companies have diversified the supply chain, and increased the availability of Berubicin, mitigating the risks of COVID-19 in clinical trial strategies.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Surgical imaging company Imagin Medical Inc. has developed a proprietary technology that enhances surgeons’ efforts to identify the full extent of bladder cancers and remove them
• Imagin’s i/Blue Imaging (TM) System uses blue light in combination with a fluorescent contrasting agent that highlights the tumor on an endoscope’s camera display to help surgeons remove the cancerous cells more completely than the white light standard
• Bladder cancer is the fourth most common cancer in men and the second most common genitourinary cancer
• The American Cancer Society forecasts that, during this year, about 81,400 new cases of bladder cancer would be reported and that about 17,980 people would die from the disease
• While Imagin’s initial focus is on making its technology effective and available for fighting bladder cancer, the company intends to expand its platform to work with other minimally invasive surgical procedures such as thoracic and laparoscopic

The rich blue of a daytime sky and the darker hues of a deep pool of water can evoke images of serenity for the troubled mind, while high-energy blue light at the darker end of the visible light spectrum serves health-enhancing functions such as boosting individuals’ alertness, helping memory and cognitive function, and elevating mood. It also helps to regulate the body’s natural wakefulness and sleep cycle known as the circadian rhythm (https://ibn.fm/kvAYr).

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is harnessing the virtues of blue light in an additional, health-enhancing way. By utilizing the company’s proprietary i/Blue Imaging (TM) System with a contrast agent, surgeons will be able to better visualize the parameters of cancers and then develop the appropriate response strategy.

Imagin’s platform is being developed for use in bladder cancer surgery. It relies on the drug, Cysview, which rapidly infiltrates the cancer cells and causes them to glow bright pink under blue light. The drug is administered just before surgery and the blue light is used endoscopically to locate and examine the tumor.

Endoscopic and laparoscopic imaging technology have revolutionized surgical medicine with their minimally invasive advanced optics and light sensors. Cameras and recording devices attached to long, thin tubes inserted into the body through the digestive tract or a small incision elsewhere have eliminated the need for many open surgical procedures — reducing patient anxieties and improving recovery times in the process (https://ibn.fm/VGZDU).

However, the utilization of blue light enhancement of endoscopic procedures is a relatively new development, and most surgical centers have yet to adopt it as part of their protocols. Imagin reports in a recent company webinar that the blue light procedure helps identify 25 percent more tumors but that it is used in less than 10 percent of urological procedures, despite its recommendation by the American Urological Association.

“Clearly one of the big things with patients of bladder cancer is getting it right and getting it right the first time. And we’ve been relying on white light cystoscopy for way too long,” Dr. Ashish M. Kamat, the director of the urologic oncology fellowship at the University of Texas M.D. Anderson Cancer Center in Houston, says during an interview for the webinar (https://ibn.fm/IGuqQ).

“This year itself, in 2020, we’ve had multiple efforts, editorials and workshops, to try and improve the quality of TRBT (transurethral resection of bladder tumor), and one of the ways to do that is enhanced optical cystoscopy,” Kamat adds. “Blue light really allows us to see these tumors that the naked eye, with white light, just cannot see. It allows us to do a better diagnosis, a better resection, but unfortunately a large percentage of the market today still does not have access to blue light and hence a large percentage of patients just don’t have access to the best technology that there is to offer for resection. It’s a shame!”

One benefit of Imagin’s technology is that it “addresses the limiting factors of” current systems by making its surgical light source, video camera and data recording technology adaptable to almost any scope already on the market. The light source then displays white and blue light images side-by-side on the surgeon’s monitor without a need to toggle back and forth between one image and the other.

At the beginning of 2020, the American Cancer Society estimated about 81,400 new cases of bladder cancer would be reported during the year — the vast majority of them in men (https://ibn.fm/KpvOR). The organization anticipates that, of the more than 600,000 living patients already diagnosed and treated for bladder cancer at least once, about 17,980 of them will die  . Bladder cancer is thus the second most common malignancy of the genitourinary system after prostate adenocarcinoma (https://ibn.fm/MFVl1). It is the fourth most common cancer overall in men, according to the ACS. Bladder cancer has the highest recurrence rate of all cancers at more than 50 percent, meaning patients have significant reason to worry that their cancer will return after surgery.

While Imagin’s initial focus is on improving bladder cancer surgeries, the company intends to expand its technology for other minimally invasive surgical procedures in the future, including laparoscopic, colorectal, and thoracic that use a variety of contrast dye agents, illumination sources and physical entry points.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• The Social Media Strategies Summit First Responders is a virtual conference that will take place February 2-3, 2021, and offers a unique selection of social media expert and first responders from across the country
• Attendees of the virtual conference will receive unique opportunities for one-on-on and live Q&A sessions with presenters and others in attendance
• For over a decade, the Social Media Strategies Summit has been bringing together professionals around the same common goal of upgrading online marketing, branding, and customer relations, while providing them with the platform and expertise to move forward

Since 2009, the Social Media Strategies Summit has been producing conferences for thousands of attendees interested in upgrading their online marketing, branding, and customer relations. The upcoming 2021 virtual conference is geared toward a new set of professionals: first responders and public safety professionals.

The Social Media Strategies Summit First Responders conference is scheduled to take place online February 2-3, 2021, with a vast network of agency peers in attendance from across the country. The platform will allow attending industry experts to share experiences, learn new social media strategies, and collaborate with one another virtually.

The Social Media Strategies Summit’s virtual platform offers attendees a unique participation experience, optimizing education, learning, and networking during the First Responders’ event of 2021. The conference will have three major components:

• Exhibit Hall – The virtual exhibit hall will be much like an in-person event (only online), creating an area where attendees can interact with and learn more from the vendor sponsors of the exhibit. Attendees have the opportunity to download marketing materials, learn about new services and solutions that align with their organizational needs, and chat with sales representatives one-on-one.
• Session Rooms – The virtual session rooms allow attendees to participate in activities such as live chats with other attendees, receive answers to questions through a live Q&A after each scheduled presentation, and rewatch any portion they have missed after the conference is over.
• Networking Room – Summit opportunities include a virtual networking room where attendees get the chance to further engage with others in attendance and the featured speakers. Networking rooms have topic tables to engage further based on a set area, allow for participation in a real-time event feed, and the opportunity to chat or set up one-on-one meetings through the event’s portal.

During the two-day conference, attendees who have purchased tickets will have the opportunity to attend virtual presentations from social media giants and gain first-hand advice from other first responders. A total of 15 public sessions will be organized over the two days of the event, promising fresh perspectives and valuable insights into social media for first responders, provided by industry experts from different companies and institutions, including Facebook, UC Davis Fire Department, Fort Worth Police Department, Las Vegas Fire & Rescue, ArchiveSocial, and many more.

In addition to the main event, the conference will also feature on-demand virtual sessions:

• The One-Person Social Team: Scrappy Social Media Strategies with Big Impact – Katelyn Brower, Social Media Manager, Sterling
• Attention is Everything: Using Video to Build Brand Love and Drive Attention – Charlene Tassinari & Carli Potock, Founders, Canvas+Co
• How to Choose & Optimize the Right Social Platform for your Brand – Vanessa Williams, Director of Integrated Strategy & Promotions, and Joanie Leider, Community Manager, both from Ignite Social Media
• Copy and Creative Tips on Twitter for Higher Engagement – Sara Zaccaro, Global Paid Social Strategy Lead, Accenture

Discounted early-bird tickets for those who wish to attend the Social Media Strategies Summit First Responders virtual conference are available until January 14. After that, the general admission price will go into effect, requiring attendees to “pay at the door.”

For more information or to register, visit the event’s website at www.SocialMediaStrategiesSummit.com.

• Health Canada recently granted psilocybin testing access to selected physicians
• Psilocybin mushrooms shown to help patients suffering from addiction, mental health issues
• Pure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021

In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government has recently granted access to psilocybin or “psychedelic” mushrooms to several physicians for use in patients with addiction and/or mental health issues (https://ibn.fm/j9ZAO). In line with anticipated legislation expected to loosen restrictions on psilocybin mushrooms, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian plant-based extraction company with a new vertical in functional mushrooms, is currently positioning itself to be the dominant extraction company and leader in the rapid development and commercialization of functional and medicinal products. Hajdu’s comments were part of a discussion on several health-related topics at a recent Vancouver B.C. virtual townhall with the Honourable Hedy Fry, a Canadian parliament representative. In response to Fry’s questions concerning the use of psilocybin mushrooms, Hajdu disclosed that the government was taking the discussion into the mainstream by granting some physicians access to the mushrooms for testing purposes. “Health Canada approved some physicians access to psilocybin mushrooms to test,” said Hajdu. “We are still testing these mushrooms and their effects, and we are taking these discussions out of the shadows and into more of a mainstream conversation.” In anticipation of relaxed laws around the use of psilocybin mushrooms, Pure Extracts is building-out its existing cannabis-processing infrastructure to accommodate mushroom extraction processes as part of its overall market penetration strategy. The Company operates out of its state-of-the-art facility in British Columbia, Canada that is built to European Union GMP standards for the purpose of obtaining EU-GMP certification in order to export to European countries, where both cannabis and functional mushroom products are legal for sale and consumption. Rather than operate in the saturated cultivation market, Pure Extracts instead purchases in bulk from Licensed Producers for further extraction processing via a Health Canada Standard Processing License granted to Pure Extracts Manufacturing Corp., its wholly-owned subsidiary. Along with both cannabis and hemp biomass processing and white labeling for Licensed Producers, the Company has also developed private label products that include the mushroom-based ‘Pure Mushrooms’ line and the ‘Pure Pulls’ line of cannabis products. “We intend to launch these products in Q1 from an online portal that we are developing,” said Pure Extracts’ CEO, Ben Nikolaevsky (https://ibn.fm/BplTK). “Functional mushrooms have been identified as the new ‘wonder’ product in the wellness space and have been rapidly growing in popularity, so this is a very exciting move for us.” Pure Extracts was incorporated under the British Columbia Business Corporations Act and is headquartered just north of Whistler, British Columbia. Along with being granted its Standard Processing License by Health Canada on September 25, 2020, the Company also started trading on the Canadian Securities Exchange on November 5, 2020 under the symbol “PULL”. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Timing of expansion into CBD market correlated with passing of 2018 Farm Bill
• MORE Act decriminalizes marijuana, has passed the House
• Reclassification of cannabis by the UN may increase medical research, impact legalization efforts globally

Founded in 2012, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) quickly earned a reputation as one of the fastest-growing and most innovative lifestyle brands. Now a leading producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, WTER’s flagship product was a premium 8.8 pH balanced alkaline drinking water produced through an innovative, state-of-the-art proprietary electrolysis process. In 2018, WTER became publicly traded thanks to a disciplined growth strategy that soon expanded into the CBD space. The timing was perfect for this new endeavor. The 2018 Farm Bill passed, and CBD had become a buzz word in the health and wellness industry. WTER partnered with Centuria Foods and launched A88CBD(TM) in 2020, a product line (https://ibn.fm/UH2fn) that only uses CBD sourced from hemp lawfully grown and processed within the United States. But the United States hasn’t always been supportive of CBD. In 1937 under the Marihuana Tax Act, all parts of the marijuana plant were made illegal. In 1970 under the Controlled Substances Act, cannabis of any kind was prohibited. That changed in 2018 with the Farm Bill’s passing. The 2018 Farm Bill played a large part in WTER’s story and expansion by allowing for hemp cultivation and the selling of hemp products under 0.3 percent THC (https://ibn.fm/zTkyS). As new bills make their way across the House and Senate floors, WTER is looking forward to what it means for the company and the industry at large. New bills could lead to the long-awaited FDA guidance on CBD-infused consumer products. An example of this type of legislations is the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act) of 2019, which passed the House and is now awaiting approval in the Senate and then the White House. This marks the first time that a federal legislative body has ever voted to decriminalize marijuana. If the MORE Act passes both House and Senate and the President’s desk, marijuana will be removed from the list of scheduled substances. Criminal penalties will also be removed  (https://ibn.fm/SJVCe). This is a strong step forward in removing stigmas and creating therapeutic options for consumers. In addition to decriminalizing marijuana, the bill will put into motion several other changes, including:

• The ability for cannabis-related businesses to acquire loans and services not previously available
• Cannabis will no longer be used as a reason to allow for deportation or the rejection of asylum claims
• Those in prison for marijuana charges will receive a sentencing review for potentially reduced sentencing
• Federal cannabis sales tax of 5% of the sale price to pay for opportunity grants for communities most impacted by the war on drugs

The MORE Act is a step toward legal cannabis diversity and inclusion. While the future of the bill remains in question, the fact that it has progressed as far as it has indicates significant progress for cannabis in both government and popular support. And the growing acceptance and changes aren’t only being seen in the United States. The United Nations recently voted to reclassify cannabis as a less dangerous drug (https://ibn.fm/hohwB). This change holds the potential to increase medical research into the therapeutic benefits and impact legalization efforts globally. “With the apparent change in administration in the U.S., we believe that the FDA guidance on CBD will be forthcoming soon,” said WTER CEO Richard Wright (https://ibn.fm/B4qgc). “Being the National Consumer Products goods company, we feel we are positioned very well to take advantage of any changes that would allow us to sell in all the states.” For more information, visit the company’s website at www.TheAlkalineWaterCo.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• What: Clinical Document World summit, organized by Lincoln Health Network
• Where: Taking place online, with registration at https://ibn.fm/x3biD
• When: Feb. 24-26, 2021
• The summit will help professionals in the fields of pharmaceuticals, biotech, and medical device manufacture or utilization to improve their documentation experiences
• Interactive platform allows attendees to seek new information and answers to old questions from speakers and other attendees using one-on-one as well as group features

The demands of clinical documentation, particularly in light of the increased requirements resulting from the Affordable Care Act, have a tendency to produce clinician burnout, “increased cognitive load,” distractions and still result in the loss of some information (https://ibn.fm/qxjC6).

In the modern era, professionals expect to avail themselves of technological advancements to improve their performance and eliminate obstacles to productivity, and certainly automated features such as artificial intelligence-enhanced digital scribes can help capture conversations and convert them to documentation but specialized forms and other individualized elements of the clinical setting may prevent a once-size-fits-all approach.

Lincoln Health Network’s (“LHN”) Clinical Document World summit aims to deliver a one-stop learning experience for life science professionals battling to improve their documentation resources and procedures, as well as through complementary partnerships with other professionals in the fields of pharmaceuticals, biotech, and medical device manufacture or utilization (https://ibn.fm/HZmTS).

The three-day Clinical Document World event will take place Feb. 24-26 in a virtual setting given the continuing dangers posed by the COVID-19 pandemic to large public gatherings. Utilizing LHN’s virtual platform, the summit will facilitate networking, Q&A needs and interactive introductions to new things in as seamless a transition as possible from in-person gatherings. Attendees can instant message seminar presenters and other attendees at any time during the event or schedule a more personal video chat with someone.

Virtual session rooms, an exhibit hall, a networking lounge, a resource page and a real-time feed all help make the experience educational and able to generate new usefulness even after the summit has ended. The networking lounge provides great opportunities for productivity in a group, and the interactive exhibit hall allows attendees to browse some of the latest technology and services with the potential to schedule a live demo to determine if something may help the attendees’ organizations.

The 20-plus faculty roster members come from a variety of companies where they have amassed experience in trial master files (“TMF”) operations, inspection readiness, risk management and other clinical development avenues.

Following the opening day’s keynote speech on the “Impact of a Strategic Document Strategy for CRO, Sites, and Sponsors,” sessions and panels will focus on strategies for global clinical operations, metrics-friendly governance structures to accumulate useful data for inspection readiness, leveraging emerging technologies, ensuring clinical quality standards in documentation, and other related subjects.

Early bird price rates end Jan. 21, although standard and last chance ticketing will continue to be available until the event.

For further information on registration and tickets, as well as how to participate as a speaker, visit the event’s website at https://ibn.fm/6Y31C.

• Average income of a pro-esports player is $400,000
• Audience for esports is expected to reach 495 million by the end of 2020
• eSports betting market forecasted at $17.2 billion globally by the end of 2020

Mobius Interactive, an online gaming operator, is capitalizing on the quickly growing eSports segment. Through its brand, MobiusBet, the company attracts a network of high-net-worth gamers worldwide with loyalty programs, targeted gamification and product merchandising. The world of gaming has changed significantly in the last four decades, and so have the rewards. The earliest known video game competition took place at Stanford University on Oct. 19, 1972. During that competition, players competed on Spacewar for the grand prize of a one-year subscription to “Rolling Stone” (https://ibn.fm/Vfo6c). Today pro players compete online for large sums of money, and fans place bets on their favorites. In 2019, 44 million people attended the final of the League of Legends World Championship. The pandemic of 2020 only accelerated the industry’s growth. There are currently 12 professional esports leagues across the globe, 120 franchised teams and an estimated 1,000 professional players whose average salary is close to $400,000 (https://ibn.fm/3iJM4). eSsports is expected to reach a value of $1.1 billion by the end of 2020, a 15.7% increase from the previous year. The audience for esports is also growing, at 495 million this year, up 11.7% from 2019 (https://ibn.fm/RseWi). And by 2023, viewership is expected to reach 646 million (https://ibn.fm/Yj0oC). With this anticipated audience growth comes a heightened eSports betting market forecasted at $17.2 billion globally by the end of 2020 (https://ibn.fm/pFPBf). Mobius provides players with access to more than 34 eSports games and mega tournaments. Available around the clock, the platform has a wide range of functionalities, mystery jackpots, cutting-edge technology, and live and pre-match odds. The company has partnered with UltraPlay, a globally recognized, award-winning, unrivaled eSports odds and platform supplier. The esSports industry is booming, and Mobius is ideally positioned to see the greatest benefit from the boom. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius